New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
23rd March 2023
UK: Scottish National Party (SNP) MP Ronnie Cowan has again raised in Parliament the issue of industrial hemp, saying: “The industry is telling me that it can create 105,000 jobs and pay £1bn in tax if it is allowed to grow.” He suggested members of the industry should be allowed to meet “the relevant minister” in order to make their case.
17th March 2023
2nd March 2023
UK: The Medicines and Healthcare Products Regulatory Agency (MHRA) has given notice through the Interactive Drug Analysis Profile, which provides an overview of spontaneous suspected adverse drug reactions (ADRs) reported through the Yellow Card Scheme, that the number of CBD-related notified reactions had risen to 874, including 186 serious and ten fatal. However, as the MHRA website states: “It is important to note that reported adverse reactions have not been proven to be related to the drug, and should not be interpreted as a list of known side effects.” Furthermore, media reports claim the incidents might be related to commercial interests of the makers of Epidyolex.
17th February 2023
6th February 2023
27th January 2023
19th December 2022
28th November 2022
3rd November 2022
27th October 2022
UK: The Advertising Standards Authority (ASA) issued a ruling yesterday ordering the removal of advertorials promoting Blessed CBD in the media. The ASA upheld several claims about product health claims and paid editorials. It said companies must ensure that ads don’t make medicinal claims for unlicensed products and that any general health claims are accompanied by a specific authorised health claim – no health claims have been authorised for CBD products. In addition, companies must ensure that marketing communications are clearly identifiable to avoid misleading consumers.
13th October 2022
UK: The government has no plans to change the scheduling of cannabis, following reports that home secretary Suella Braverman was considering making it a Class A drug, the BBC reports. The prime minister’s official spokesman said there were no plans to change the laws around cannabis and that the priority was on “cracking down on illegal drugs and the crime they drive”.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.